The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma

Tengfei Ma, Chad C. Wiggins, Breanna Kornatowski, Raed Hailat, Andrew J. Clayburn, Winston Guo, Patrick W. Johnson, Jonathon W. Senefeld, Stephen A. Klassen, Sarah E. Baker, Katelyn A. Bruno, DeLisa Fairweather, R. Scott Wright, Rickey E. Carter, Chenxi Li, Michael J. Joyner, Nigel Paneth

Abstract

Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.

Introduction

Early in the COVID-19 pandemic, convalescent plasma (CP)—antibody-rich plasma from recovered individuals—was widely deployed under emergency protocols. While its safety profile was established early on, its specific efficacy and the optimal timing for administration remained unclear. Specifically, researchers lacked a detailed understanding of the clinical trajectories of patients following transfusion: how quickly do they improve, and how does their baseline health status influence the outcome? This study sought to map the daily clinical trajectories of over 7,000 patients to identify which subgroups benefit most from CP and where the treatment may reach a point of futility.

Methods

The researchers utilized data from the Rapid Evaluation Project (REP), a sub-study of the Mayo Clinic’s Expanded Access Program (EAP). The study analyzed a subset of 7,180 hospitalized patients, ensuring the sample was representative of the broader national cohort in terms of demographics and baseline health.

  • Daily Tracking: Physicians provided daily status updates, categorizing patients as better, worse, or unchanged, alongside metrics such as ICU status, mechanical ventilation, discharge, or death.
  • 5-Point Ordinal Scale: To quantify progress, daily reports were mapped to a scale ranging from -2 (death) to +2 (discharge).
  • Statistical Analysis: Linear segmented analysis was used to identify "breakpoints" where recovery trajectories changed. Multivariate modeling via Generalized Estimating Equations (GEE) isolated the effects of age, sex, and severity while controlling for concomitant treatments like Remdesivir or steroids.

Results

The study identified baseline disease severity and age as the primary determinants of clinical success following CP treatment.

Clinical Trajectories and the "Sweet Spot"

Patients with mild-to-moderate illness showed the most rapid improvement, typically within the first 7 days post-transfusion. For the general cohort, mean daily scores rose from 0.16 on Day 1 to 0.82 by Day 8. However, a "9-day plateau" was observed, where the rate of recovery for most improving patients leveled off between days 7 and 9, suggesting a critical therapeutic window in the first week.

Mean scores on an ordinal scale over 20 days following convalescent plasma treatment, stratified by (A) all patients, (B) age, (C) sex, (D) disease severity, (E) ICU status, and (F) ventilator status.

Age and Severity Barriers

A striking "age ceiling" was observed: patients aged 80 and older showed almost no clinical improvement following transfusion (OR 0.25 compared to the 18-34 age group). Similarly, patients already on ventilators or in critical condition often continued a downward trajectory. Critical/end-stage patients saw their mean scores drop from -0.04 to -0.26 between Day 1 and Day 9. Mechanical ventilation (OR 0.41) and ICU admission (OR 0.47) were massive predictors of non-improvement.

Sensitivity Analysis

To ensure the findings were specific to CP, researchers analyzed the use of other standard-of-care treatments. The presence of steroids or Remdesivir changed effect sizes by less than 10%, indicating that the observed trajectories were robust and not primarily driven by other medications.

Frequency of concomitant medication use among patients in the study cohort.

Discussion

The findings suggest that while CP is a potent tool for mild-to-moderate cases, it offers diminishing returns for the elderly and provides little benefit for patients in end-stage disease.

Limitations: As an observational study within an Expanded Access Program, there was no untreated control group. Additionally, the "better/worse" status relied on physician assessment, which contains inherent subjectivity despite being anchored to clinical events.

Future Directions: Clinical use of CP should focus strictly on early-stage patients. Further research into the efficacy of a second antibody dose may be warranted for patients whose improvement stalls after the initial 7-9 day window.

Summary updated

Abstract

Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.
BibTeX
@inproceedings{ma2022role,
  author = {Tengfei Ma and Chad C. Wiggins and Breanna Kornatowski and Raed Hailat and Andrew J. Clayburn and Winston Guo and Patrick W. Johnson and Jonathon W. Senefeld and Stephen A. Klassen and Sarah E. Baker and Katelyn A. Bruno and DeLisa Fairweather and R. Scott Wright and Rickey E. Carter and Chenxi Li and Michael J. Joyner and Nigel Paneth},
  title = {{The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.707895},
}
Figure